肾细胞癌中 18F-FDG PET/CT 检测到纳武单抗和卡博替尼免疫疗法诱发甲状腺功能障碍。
Nivolumab and Cabozantinib Immunotherapy Induced Thyroid Dysfunction Detected on 18F-FDG PET/CT in Renal Cell Carcinoma.
发表日期：2024 Aug 28
作者：
Moulish Reddy, Mudalsha Ravina, Harish Goyal, Amit Kumar, Rutuja Kote
来源：
CLINICAL NUCLEAR MEDICINE
摘要：
靶向免疫疗法成为最先进的癌症治疗方法。活化 T 细胞上表达的程序性死亡 1 (PD-1) 可以逆转免疫抑制并导致 T 细胞活化。 Nivolumab 是一种 PD-1 免疫检查点抑制剂抗体，是一种完全人源免疫球蛋白 G4，可阻断 PD-1 并促进抗肿瘤免疫。卡博替尼（酪氨酸激酶抑制剂）抑制血管内皮生长因子受体1、2和3的酪氨酸激酶活性。由于增强正常组织的免疫反应，可能会发生免疫相关的不良事件。甲状腺功能障碍是一种常见的免疫相关不良事件，可在治疗后 18F-FDG PET/CT 扫描中观察到。版权所有 © 2024 Wolters Kluwer Health, Inc. 保留所有权利。
Targeted immunotherapy became the most advanced approach for cancer treatment. Programmed death-1 (PD-1) expressed on activated T cells can reverse immune suppression and cause T-cell activation. Nivolumab, a PD-1 immune checkpoint inhibitor antibody that is a fully human immunoglobulin G4, blocks PD-1 and promotes antitumor immunity. Cabozantinib (tyrosine kinase inhibitor) inhibits the tyrosine kinase activity of vascular endothelial growth factor receptors 1, 2, and 3. As a result of enhancing immune response in normal tissues, immune-related adverse events can occur. Thyroid dysfunction is a common form of immune-related adverse event and seen on 18F-FDG PET/CT scans post therapy.Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.